SAN FRANCISCO, Feb. 18, 2021 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25, 2021 at 5:00 PM ET.
The presentation will be available through the SVB Leerink conference portal and an archived webcast will also be accessible in the investor section of 89bio’s website.
About 89bio
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.
Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com
Media Contact:
Peter Duckler
773-343-3069
pduckler@w2ogroup.com
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for…
MARLBOROUGH, Mass.--(BUSINESS WIRE)--$HOLX #earnings--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release…
Complements Family Interactions & Supports Sandwich Generation of Caregivers with Daily Phone Calls to Seniors…
"Comprehensive Analysis of MENA's AI Healthcare Market: Emerging Opportunities and Challenges, with a Projected CAGR…
SHERBROOKE QC, July 2, 2025 /PRNewswire/ - Global Excel Management Inc. (Global Excel) is pleased…
The evaluation will include 1,000 unique procedures across 20 centers worldwide to capture real-world evidence…